Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services


Evotec AG and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company announced that they have entered into agreements whereby Evotec will provide pharmaceutical discovery and chemical development services to P&GP. Under the terms of the agreements, P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.

A relationship between Evotec and P&GP started at the end of 2004 with a pilot screening programme for a challenging P&GP therapeutic target. This work was successfully completed, and subsequently the work has been expanded to include additional targets, and the companies have signed additional agreements for medicinal chemistry and pharmaceutical development scale-up services.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionising chemistry?